Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii

García, PatriciaGuijarro-Sánchez, PaulaLasarte-Monterrubio, CristinaMuras, AndreaAlonso-García, IsaacOuteda-García, MichelleMaceiras, RominaFernández-López, María del CarmenRodríguez-Coello, AriannaGarcía-Pose, AndreaBlanco Martín, TaniaGonzález-Pinto, LucíaArca-Suárez, JorgeVázquez-Ucha, Juan CarlosBou, GermánBeceiro Casas, Alejandro2025-01-292025-01-292024-12-02García P, Guijarro-Sánchez P, Lasarte-Monterrubio C, Muras A, Alonso-García I, Outeda-García M, Maceiras R, Fernández-López MDC, Rodríguez-Coello A, García-Pose A, Blanco-Martín T, González-Pinto L, Arca-Suárez J, Vázquez-Ucha JC, Bou G, Beceiro A; Spanish National Acinetobacter spp. 2020 Study Group and GEMARA-SEIMC/REIPI Enterobacterales Study Group. Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii. Biomed Pharmacother. 2024 Dec;181:117666.0753-3322http://hdl.handle.net/2183/40943Multicenter study[Abstract] Introduction: The rise in multidrug-resistant bacteria challenges clinical microbiology. Tigecycline, eravacycline, and omadacycline show promise against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. This study evaluates their activity and resistance mechanisms. Methods: Two Spanish multicentre collections of WGS-characterized carbapenemase-producing Enterobacterales (n=399) and A. baumannii (n=118) were tested. The MICs of tigecycline, eravacycline, omadacycline and classic tetracyclines were determined. WGS-guided resistome analysis, expression studies, efflux pump inhibition and cloning assays identified potential mechanisms of resistance. Results: Tigecycline and eravacycline exhibited the highest activity against the whole set of Enterobacterales (MIC50/MIC90 0.5/1 mg/L and 1/2 mg/L, respectively), and A. baumannii (MIC50/MIC90 1/2 mg/L and ≤0.25/1 mg/L, respectively). Omadacycline showed no improvement relative to classic tetracyclines (MIC50/MIC90 values of 8/32 mg/L and 8/16 mg/L for Enterobacterales and A. baumannii, respectively). Resistance mechanisms in Enterobacterales included efflux pumps (AcrAB-TolC, OqxAB) and mutation in their regulatory genes. In A. baumannii, adeS gene mutations and adeABC upregulation decreased tigecycline activity. The prevalent sequence types with reduced susceptibility to eravacycline and tigecycline were ST307 in K. pneumoniae and ST2 in A. baumannii. Conclusion: Eravacycline remains a key agent for the treatment of bacterial infections exhibiting promising efficacy against multidrug-resistant pathogens. As an empirical antibiotic it could be a good alternative for severe infections caused by CPE or CRAB, however, its clinical use is limited by the absence of standardized breakpoints. Resistance mechanisms, including efflux pumps and gene mutations, vary among isolates. High-risk clones like K. pneumoniae ST307 and A. baumannii ST2 underscore the necessity of prudent antibiotic use.engCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)http://creativecommons.org/licenses/by-nc-nd/3.0/es/Acinetobacter baumanniiAntimicrobial resistanceCarbapenemase-producing EnterobacteralesEravacyclineOmadacyclineTigecyclineActivity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish collections of carbapenemase-producing Enterobacterales and Acinetobacter baumanniijournal articleopen access10.1016/j.biopha.2024.117666